Aika Miya

483 total citations
39 papers, 312 citations indexed

About

Aika Miya is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Aika Miya has authored 39 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Molecular Biology and 12 papers in Surgery. Recurrent topics in Aika Miya's work include Diabetes Treatment and Management (25 papers), Metabolism, Diabetes, and Cancer (16 papers) and Diabetes Management and Research (15 papers). Aika Miya is often cited by papers focused on Diabetes Treatment and Management (25 papers), Metabolism, Diabetes, and Cancer (16 papers) and Diabetes Management and Research (15 papers). Aika Miya collaborates with scholars based in Japan, United States and Canada. Aika Miya's co-authors include Tatsuya Atsumi, Akinobu Nakamura, Hideaki Miyoshi, Kyu Yong Cho, Hiroshi Nomoto, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, So Nagai and Kohei Yamamoto and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Scientific Reports and Medicine.

In The Last Decade

Aika Miya

34 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aika Miya Japan 10 252 105 93 76 37 39 312
Toshiki Otoda Japan 7 106 0.4× 79 0.8× 49 0.5× 81 1.1× 26 0.7× 21 242
Yunyi Le China 8 178 0.7× 133 1.3× 150 1.6× 44 0.6× 59 1.6× 16 311
P. Buffier France 9 107 0.4× 55 0.5× 70 0.8× 143 1.9× 21 0.6× 19 269
Sangeeta Sawhney United States 9 475 1.9× 73 0.7× 330 3.5× 27 0.4× 87 2.4× 19 514
Yoshinori Ozeki Japan 9 121 0.5× 45 0.4× 91 1.0× 58 0.8× 48 1.3× 23 303
Sinan Tanyolaç Türkiye 7 100 0.4× 97 0.9× 45 0.5× 48 0.6× 30 0.8× 11 264
Tae Keun Oh South Korea 10 166 0.7× 111 1.1× 90 1.0× 11 0.1× 39 1.1× 27 256
Diego Bailetti Italy 10 95 0.4× 55 0.5× 54 0.6× 92 1.2× 37 1.0× 20 229
Diane L. Möller-Goede Netherlands 5 313 1.2× 101 1.0× 140 1.5× 45 0.6× 18 0.5× 7 340
Yingying Wei China 10 78 0.3× 79 0.8× 65 0.7× 29 0.4× 11 0.3× 26 274

Countries citing papers authored by Aika Miya

Since Specialization
Citations

This map shows the geographic impact of Aika Miya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aika Miya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aika Miya more than expected).

Fields of papers citing papers by Aika Miya

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aika Miya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aika Miya. The network helps show where Aika Miya may publish in the future.

Co-authorship network of co-authors of Aika Miya

This figure shows the co-authorship network connecting the top 25 collaborators of Aika Miya. A scholar is included among the top collaborators of Aika Miya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aika Miya. Aika Miya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Oe, Yuki, Hiroshi Nomoto, Kyu Yong Cho, et al.. (2025). Efficacy and safety of tirzepatide in subjects with type 2 diabetes and chronic kidney disease: a prospective, two-arm observational study. Therapeutic Advances in Endocrinology and Metabolism. 16. 2465747496–2465747496.
2.
Nomoto, Hiroshi, Yuki Yamauchi, Kazuno Omori, et al.. (2024). Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease. Diabetes & Metabolism Journal. 48(3). 473–481. 5 indexed citations
3.
4.
Miya, Aika, Akinobu Nakamura, Hiroshi Nomoto, Hiraku Kameda, & Tatsuya Atsumi. (2024). Positive association between the proinsulin-to-C-peptide ratio and prolonged hyperglycemic time in type 2 diabetes. Endocrine Journal. 71(4). 403–408.
5.
6.
7.
8.
9.
Nomoto, Hiroshi, Yuka Takahashi, Hiroki Yokoyama, et al.. (2023). Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis. Pharmaceutics. 15(8). 2163–2163. 9 indexed citations
10.
11.
12.
13.
14.
Miya, Aika, Akinobu Nakamura, Kyu Yong Cho, et al.. (2020). Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. Journal of Diabetes Investigation. 12(8). 1395–1399. 1 indexed citations
15.
Nomoto, Hiroshi, Akinobu Nakamura, Kyu Yong Cho, et al.. (2020). Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes. Journal of Diabetes Investigation. 12(2). 176–183. 10 indexed citations
16.
Miya, Aika, Akinobu Nakamura, Hideaki Miyoshi, et al.. (2020). Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study. Journal of Diabetes Investigation. 11(4). 964–970. 6 indexed citations
17.
Miya, Aika, Akinobu Nakamura, Hiroshi Nomoto, et al.. (2020). Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment. Journal of Diabetes Investigation. 12(5). 738–746. 15 indexed citations
18.
Cho, Kyu Yong, Akinobu Nakamura, Kazuno Omori, et al.. (2020). Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone. Journal of Diabetes Investigation. 12(7). 1272–1277. 39 indexed citations
19.
Nakamura, Akinobu, Kohei Yamamoto, Hiroshi Nomoto, et al.. (2018). Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation. 10(3). 699–705. 29 indexed citations
20.
Takahashi, Kiyohiko, Kyu Yong Cho, Akinobu Nakamura, et al.. (2018). Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation. 10(2). 429–438. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiki Otoda Breakdown of academic impact, for papers by Yunyi Le Breakdown of academic impact, for papers by P. Buffier Breakdown of academic impact, for papers by Sangeeta Sawhney Breakdown of academic impact, for papers by Yoshinori Ozeki Breakdown of academic impact, for papers by Sinan Tanyolaç Breakdown of academic impact, for papers by Tae Keun Oh Breakdown of academic impact, for papers by Diego Bailetti Breakdown of academic impact, for papers by Diane L. Möller-Goede Breakdown of academic impact, for papers by Yingying Wei
Rankless by CCL
2026